[1] Hunter DJ. Osteoarthritis. Best Pract Res Clin Rheumatol. 2011;25(6):801-814. [2] Ding M, Danielsen CC, Hvid I. Age-related three-dimensional microarchitectural adaptations of subchondral bone tissues in guinea pig primary osteoarthrosis. Calcif Tissue Int. 2006;78 (2):113-122. [3] Goldring SR. Role of bone in osteoarthritis pathogenesis. Med Clin North Am. 2009;93(1):25-35, xv. [4] Hayami T, Pickarski M, Zhuo Y, et al. Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis. Bone. 2006;38(2):234-243. [5] Kwan Tat S, Lajeunesse D, Pelletier JP, et al. Targeting subchondral bone for treating osteoarthritis: what is the evidence? Best Pract Res Clin Rheumatol. 2010;24(1):51-70. [6] Castañeda S, Roman-Blas JA, Largo R, et al. Subchondral bone as a key target for osteoarthritis treatment. Biochem Pharmacol. 2012;83(3):315-323. [7] Hunter DJ, Spector TD. The role of bone metabolism in osteoarthritis. Curr Rheumatol Rep. 2003;5(1):15-19. [8] Bellido M, Lugo L, Roman-Blas JA, et al. Subchondral bone microstructural damage by increased remodelling aggravates experimental osteoarthritis preceded by osteoporosis. Arthritis Res Ther. 2010;12(4):R152. [9] Carbone LD, Nevitt MC, Wildy K, et al. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum. 2004;50(11):3516-3525. [10] Papaioannou NA, Triantafillopoulos IK, Khaldi L, et al. Effect of calcitonin in early and late stages of experimentally induced osteoarthritis. A histomorphometric study. Osteoarthritis Cartilage. 2007;15(4):386-395. [11] Bellido M, Lugo L, Roman-Blas JA, et al. Improving subchondral bone integrity reduces progression of cartilage damage in experimental osteoarthritis preceded by osteoporosis. Osteoarthritis Cartilage. 2011;19(10): 1228-1236. [12] Christgau S, Tankó LB, Cloos PA, et al. Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen- receptor modulator (SERM). Menopause. 2004; 11(5):508-518. [13] 李西海,陈文列,刘献祥.补肾柔肝法防治骨性关节炎作用机制探讨[J].福建中医药大学学报,2011,21(2):66-69. [14] 林木南,刘献祥.透骨消痛方治疗膝骨性关节炎30例[J].福建中医药,2005,36(4):5-16 [15] 刘献祥,李西海,周江涛,等.透骨消痛胶囊防治膝骨性关节炎的机理研究[J].中国中西医结合杂志,2007,27(1):50-54. [16] Zheng CS, Ye HZ, Xu XJ, et al. Computational pharmacology study of tougu xiaotong granule in preventing and treating knee osteoarthritis. Chin J Integr Med. 2009;15(5):371-376. [17] 吴追乐,李西海,吴广文,等.透骨消痛胶囊含药血清对软骨细胞线粒体凋亡通路的影响[J].中华中医药杂志,2011,26(2):343-346. [18] 叶蕻芝,李西海,梁文娜,等.透骨消痛胶囊含药血清对兔软骨细胞增殖影响的研究[J].中国临床药理学与治疗学,2009,14(6): 624-628. [19] 黄云梅,陈文列,刘献祥,等.透骨消痛胶囊对骨性关节炎影响的组织化学研究[J].中国中医骨伤科学杂志,2011,19(1):1-3. [20] 李民,郭逸尔,刘献祥,等.透骨消痛胶囊干预膝骨性关节炎软骨下骨重塑的分子机制[J].中国组织工程研究,2012,16(15): 2669- 2673. [21] Nakayama Y, Yang L, Takai H, et al. Fibroblast growth factor 2 and forskolin induce mineralization-associated genes in two kinds of osteoblast-like cells. J Oral Sci. 2012;54(3):251-259. [22] Chen H, Kolman K, Lanciloti N, et al. p53 and MDM2 are involved in the regulation of osteocalcin gene expression. Exp Cell Res. 2012;318(8):867-876. [23] Alaiyan B, Ilyayev N, Stojadinovic A, et al. Differential expression of colon cancer associated transcript1 (CCAT1) along the colonic adenoma-carcinoma sequence. BMC Cancer. 2013;13(1):196. [24] Trouvin AP, Goëb V. Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clin Interv Aging. 2010;5:345-354. [25] Pivonka P, Zimak J, Smith DW, et al. Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling. J Theor Biol. 2010;262(2):306-316. [26] Liu C, Walter TS, Huang P, et al. Structural and functional insights of RANKL-RANK interaction and signaling. J Immunol. 2010;184(12):6910-6919. [27] Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008; 473(2):139-146. [28] Sakao K, Takahashi KA, Mazda O, et al. Enhanced expression of interleukin-6, matrix metalloproteinase-13, and receptor activator of NF-kappaB ligand in cells derived from osteoarthritic subchondral bone. J Orthop Sci. 2008;13(3): 202-210. |